Cancer drug tazemetostat gets Long-Term safety check in rollover trial

NCT ID NCT02875548

Completed Disease control Sponsor: Epizyme, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study offers continued access to tazemetostat for 58 people with various cancers who already benefited from the drug in earlier trials. The main goal is to monitor long-term safety and side effects. Participants must have shown clinical benefit from tazemetostat before joining.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: tazemetostat (a targeted cancer drug)
What this could lead to: If successful, this study could confirm that long-term use of tazemetostat is safe for people with certain cancers, supporting its continued use as a treatment option.
What could go wrong: This is a rollover study, not a new treatment test, so it won't prove whether tazemetostat works better than other options. Long-term side effects are still being monitored.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

collecting duct carcinoma diffuse large B-cell lymphoma epithelioid sarcoma follicular lymphoma mesothelioma neoplasm non-Hodgkin lymphoma synovial sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMORS DIFFUSE-LARGE B-CELL LYMPHOMA (DLBCL) EPITHELIOD SARCOMA (ES) FOLLICULAR LYMPHOMA (FL) MESOTHELIOMA NON HODGKIN LYMPHOMA (NHL) RENAL MEDULLARY CARCINOMA SYNOVIAL SARCOMA

Contacts and locations

Locations

Astera Cancer Center

East Brunswick, New Jersey, 08816, United States
Beatson, West of Scotland Cancer Centre

Glasgow, United Kingdom
CHRU de Lile- Hopital Claude Huriez

Lille, 59037, France
CHU Rennes- Hopital Pontchaillou

Rennes, 35033, France
CHU de Caen - Hôpital Côte de Nacre

Caen, 14033, France
CHU de Montpellier - Hopital Saint Eloi

Montpellier, France
California Cancer Associates For Research And Excellence, cCARE

Santa Fe, California, 92024, United States
Central Care Cancer Center

Bolivar, Missouri, 65613, United States
Centre Henri Becquerel

Rouen, 76038, France
Centre Hospitalier Lyon Sud

Pierre-Bénite, 69310, France
Clatterbridge Cancer Centre

Liverpool, L7 8XP, United Kingdom
Columbia University Medical Center

New York, New York, 10019, United States
Dana-Farber Cancer Institute

Boston, Massachusetts, 02215, United States
David H. Koch Center for Cancer Care at memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States
Geelong Hospital

Geelong, Australia
Gustave Roussay

Villejuif, 94805, France
Hammersmith Hospital

London, W12 0HS, United Kingdom
Hematology Oncology Associates of the Treasure Coast - Port St. Lucie

Port Saint Lucie, Florida, 34952, United States
Hôpital Saint Louis - AP-HP

Paris, 75010, France
Institut Bergonie

Bordeaux, 33076, France
Moffitt

Tampa, Florida, 33612, United States
Monash Health

Monash, Australia
Monash Medical Centre- Monash Campus

Clayton, 3168, Australia
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy, Klinika Endokrynologii Onkologicznej i Medycyny Nuklearnej

Warsaw, Poland
Oncology and Haematology Clinical Trials Unit

Leicester, LEI 5WW, United Kingdom
Peter MacCallum Cancer Institute

Melbourne, 3002, Australia
Pratia MCM Krakow

Krakow, 30-510, Poland
Princess Alexandra Hospital

Alexandra, Australia
S.P. Grigoreva Institute of Medical Radiology and Oncology of NAMS of Ukraine"

Kharkiv, 61024, Ukraine
The Christie NHS Foundation Trust

Manchester, United Kingdom
University Hospital (UZ) Leuven

Leuven, 3000, Belgium
University of Arizona Cancer Center

Tucson, Arizona, 85724, United States
University of Michigan

Ann Arbor, Michigan, 48109, United States
University of Pittsburgh Medical Center (UPMC) - Hillman Cancer Center

Pittsburgh, Pennsylvania, 15232, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.